Autosomal Dominant Nonsyndromic Hearing Loss 11 (DFNA11): Comprehensive Research Report

1. Disease Information

Overview: Autosomal Dominant Nonsyndromic Hearing Loss 11 (DFNA11; also written "Deafness, Autosomal Dominant 11") is a form of progressive, postlingual sensorineural hearing loss caused by heterozygous (dominant) pathogenic variants in MYO7A, the gene encoding unconventional myosin VIIa. It is one of three distinct clinical phenotypes produced by MYO7A mutations, situated at the mild end of the MYO7A disease spectrum: DFNA11 (dominant, nonsyndromic) < DFNB2 (recessive, nonsyndromic) < Usher syndrome type 1B (USH1B; recessive, syndromic — deafness plus retinitis pigmentosa and vestibular areflexia) (OMIM #601317; NIH GTR C1832475).

Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype) | #601317 | | OMIM (gene, MYO7A) | 276903 | | Allelic OMIM phenotypes | DFNB2 #600060; Usher syndrome 1B #276900 | | MONDO | MONDO:0011032 | | MedGen | C1832475 | | HGNC (gene) | HGNC:7606 (MYO7A*) | | UniProt | Q13402 (MYO7A_HUMAN) | | Gene location | 11q13.5 |

Synonyms: Deafness, autosomal dominant 11; DFNA11; MYO7A-related nonsyndromic hearing loss (dominant form); myosin VIIA-associated deafness.

Evidence basis: Data on DFNA11 derive almost entirely from aggregated multi-generational pedigrees and clinical case series (audiometric cohort studies, family linkage studies) rather than large EHR-based population datasets, reflecting its rarity — it is described as "the rarest consequence of MYO7A variants" relative to DFNB2 and USH1B (Joo et al. 2022, PMID: 35453549).

2. Etiology

Disease causal factors: DFNA11 is purely genetic/monogenic — caused by heterozygous, typically missense or in-frame deletion, pathogenic variants in MYO7A acting via a dominant mechanism (see Mechanism, below). No environmental or infectious causal factors are described for this specific dominant condition (as opposed to acquired/environmental sensorineural hearing loss more broadly).

Genetic risk factors: - Causal variants: heterozygous missense and small in-frame deletion variants in MYO7A, clustering predominantly in the motor domain (aa 65–741) and, less commonly, the MyTH4 (aa 1017–1253, 1747–1895) and IQ motif/coiled-coil regions. In a Korean cohort, motor-domain variants accounted for 66.7% (12/18) of DFNA11 variants identified (Joo et al. 2022, PMID: 35453549). - All reported autosomal dominant MYO7A variants in this cohort were missense or in-frame deletions — no truncating/nonsense variants were dominant-acting, consistent with a gain-of-function/dominant-activation mechanism rather than simple haploinsufficiency (see Mechanism). - Representative pathogenic variants: p.Arg853His (Kubota et al. 2020, PMID: 32097363); p.Arg244Pro-adjacent motor-domain variants; p.Thr1234Ser and p.Pro1244Arg in MyTH4 (associated with earlier-onset, more severe phenotypes) (PMID: 35453549); a missense variant in the motor head domain reported in a separate DFNA11 family (PMC3558421).

Environmental risk factors: Not specifically implicated in DFNA11; as with other progressive sensorineural hearing losses, noise exposure is generically counseled against to avoid accelerating any residual hearing decline, though this is extrapolated from general ADNSHL management guidance rather than DFNA11-specific data.

Protective factors: No genetic or environmental protective factors specific to DFNA11 have been identified in the literature reviewed.

Gene-environment interactions: None specifically documented for DFNA11.

3. Phenotypes

Primary phenotype — Sensorineural hearing loss (symptom/clinical sign): - Onset: Postlingual — after complete speech acquisition, "often in the first decade of life" per OMIM, though other cohorts describe onset in the second decade or later (second–fifth decade for motor-domain variants) (Joo et al. 2022, PMID: 35453549; malacards/OMIM #601317). - Severity: Mild to moderate at onset in most families; can progress to severe (Kubota 2002, PMID: 11889386, describes "moderate cochlear hearing loss beginning in the second decade"). MyTH4-domain variants are associated with more severe/profound loss (PMID: 35453549). - Progression: Gradual, progressive, affecting all frequencies over time. A detailed multi-generational study (Kim et al. 2020, PMID: 32097363) found audiometric configuration evolves with age: a "gently sloping configuration" in early childhood transitioning to a "flat configuration" after age 30; high-frequency thresholds deteriorate slowly while low-frequency thresholds, though affected later, "progressed more rapidly" once involved. Abnormal distortion product otoacoustic emissions (DPOAEs) were detectable before standard pure-tone threshold elevation in some subjects, suggesting DPOAE as a potential early/preclinical biomarker. - Laterality: Bilateral. - Suggested HP term: HP:0000407 (Sensorineural hearing impairment) or more specific HP:0000408 (Progressive sensorineural hearing impairment); HP:0000360 (Hearing impairment, general).

Vestibular dysfunction (secondary/variable phenotype): - Variably present; described as "mild" or "asymptomatic" vestibular dysfunction in some series (OMIM #601317) while a separate large-pedigree study found vestibular function "remained normal across all tested subjects" (PMID: 32097363) — indicating inter-family variability. When present, severity of vestibular impairment appears to parallel severity of the auditory phenotype within a family. - Suggested HP term: HP:0000762 (Vestibular hypofunction) or HP:0000740/HP:0002321 (Vertigo).

Absent phenotypes (distinguishing DFNA11 from allelic conditions): No retinal degeneration/retinitis pigmentosa — this is the key clinical distinguishing feature versus USH1B (OMIM #601317; PMID: 11889386). Suggested negated term: absence of HP:0000510 (Rod-cone dystrophy).

Quality of life impact: Not separately quantified for DFNA11 in the literature surveyed; general ADNSHL guidance notes progressive postlingual hearing loss affects communication, education (if pediatric onset), and social functioning, with hearing aids/cochlear implants indicated for functional impact management (PMC10296186).

Frequency among affected individuals: As an autosomal dominant condition, all variant carriers are expected to develop hearing loss (segregation in described pedigrees is consistent with high penetrance), though age of onset and severity are variable even within families.

4. Genetic/Molecular Information

Causal gene: MYO7A (HGNC:7606; OMIM *276903), chromosome 11q13.5, spans ~87 kb genomic sequence, 49 exons (48 coding). Encodes myosin VIIa, a 254 kDa, 2,215-amino-acid unconventional myosin motor protein (UniProt Q13402) (PMID: 35453549 domain data).

Protein domain architecture (from Joo et al. 2022, PMID: 35453549): - Motor domain (aa 65–741): ATP- and actin-binding; site of majority of DFNA11 variants - Neck domain (aa 745–857): five IQ motifs (calmodulin-binding lever arm) - SAH domain (aa 858–935): single alpha-helix, lever-arm extension - Coiled-coil region: between SAH and tail - Tail domain: two MyTH4 domains (aa 1017–1253; 1747–1895), two FERM domains (aa 1258–1602; 1900–2205), one SH3 domain (aa 1603–1672) - MYO7A functions as a monomer (unlike many conventional myosins), with the tail folding back onto the head-neck region in an autoinhibited state.

Variant classification and type: DFNA11 variants are exclusively missense or small in-frame deletions (never truncating) — consistent with the requirement for a stably folded, dominantly acting mutant protein (PMID: 35453549). By contrast, DFNB2 (recessive) alleles retain partial function and localize correctly to stereocilia, while USH1B alleles are typically more severely disruptive (often null/truncating) and fail to localize properly — "DFNB2 and USH1B are different ends of the same disease spectrum" (search synthesis referencing GeneReviews/PreventionGenetics data).

Allele frequency: Population-level allele frequency data specific to DFNA11-causing variants were not identified in gnomAD searches during this review; as private/family-specific dominant missense variants, they are expected to be rare/absent in gnomAD population databases, consistent with pathogenicity assessment under ACMG/AMP criteria (PM2).

Functional consequence — dominant mechanism: A 2024–2025 mechanistic study (bioRxiv 10.1101/2024.09.17.613491; PubMed: 39345484, "Select autosomal dominant DFNA11 deafness mutations activate Myo7A targeting in epithelial cells") reports that many DFNA11-patient mutations activate Myo7A targeting/trafficking in epithelial cell assays — i.e., these variants relieve the normal autoinhibited (folded-back) conformation of the myosin, causing constitutive activation/mistargeting of the motor protein. This provides a mechanistic explanation for dominant inheritance: rather than simple haploinsufficiency, mutant Myo7A is hyperactive/mistargeted, which is proposed to interfere with normal mechanotransduction complex assembly or tip-link tensioning in a dominant-negative or gain-of-function manner. A companion structure-function study found that specific IQ motifs within the myosin's lever arm regulate this targeting, at least partly independent of tail sequence.

Modifier genes: A genetic modifier of DFNA11 audiometric phenotype (affecting low- and mid-frequency thresholds) has been sought in linkage studies (Naz et al., PMID: 18667942, "In search of the DFNA11 myosin VIIA low- and mid-frequency auditory genetic modifier"), indicating intrafamilial phenotypic variability may be partly modifier-gene-driven, though the specific modifier locus was not conclusively identified in the search results retrieved.

Epigenetic information: No DFNA11-specific epigenetic (DNA methylation/histone) data were identified.

Chromosomal abnormalities: DFNA11 is caused by point/small indel variants, not large chromosomal rearrangements; no aneuploidy/translocation mechanism is described.

5. Environmental Information

No specific environmental, lifestyle, or infectious causal or exacerbating factors for DFNA11 were identified in the literature surveyed — it is a purely monogenic dominant condition. General noise-avoidance counseling applies as standard practice for progressive sensorineural hearing loss but is not DFNA11-specific evidence.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream): 1. Molecular trigger: Heterozygous missense/in-frame-deletion variant in MYO7A, predominantly in the motor domain, alters normal myosin VIIa autoregulation. 2. Molecular dysfunction: Mutant Myo7A protein shows activated/constitutive targeting rather than normal regulated (autoinhibited) trafficking, per epithelial-cell reporter assays (bioRxiv 2024.09.17.613491 / PubMed 39345484). This is distinct from the loss-of-targeting seen in USH1B-causing alleles. 3. Cellular/subcellular dysfunction: Myosin VIIa normally functions at the stereocilia upper tip-link density (UTLD) of cochlear hair cells, where a cluster of ~8+ Myo7A molecules maintains tip-link tension at rest and is required for hair-cell mechanoelectrical transduction (MET) — specifically for maintaining resting open probability of MET channels and enabling proper onset kinetics of MET currents (Nature Communications 2020, PMID: 32350269; PNAS 2024, "MYO7A is required for the functional integrity of the mechanoelectrical transduction complex in hair cells of the adult cochlea"). MYO7A also participates in ankle-link positioning in the stereocilia bundle and co-localizes with PDZD7 at the ankle-link region (eLife 2016, PMC5005036). 4. Consequence in DFNA11: Dysregulated/dominantly acting mutant myosin disrupts normal tip-link tensioning and MET complex integrity in a dose-dependent, progressive manner — producing progressive loss of MET current and progressive threshold elevation, without the profound congenital dysfunction and stereocilia disorganization seen in USH1B (where myosin VIIa is essentially non-functional/mislocalized). 5. Tissue-level consequence: Progressive cochlear hair cell (particularly stereocilia bundle) dysfunction across the cochlear frequency map, manifesting audiometrically as the age-dependent shift from sloping to flat threshold configuration described clinically (PMID: 32097363). 6. Organism-level consequence: Progressive, postlingual, bilateral sensorineural hearing loss, with variable, generally milder vestibular involvement than in USH1B (reflecting that the vestibular hair cell MET/tip-link apparatus is less severely affected by the "activating" dominant variants than by the loss-of-function USH1B alleles).

Cell types involved: Cochlear inner and outer hair cells (auditory); vestibular hair cells (variably, for the vestibular component). Suggested CL term: CL:0000855 (sensory hair cell) / CL:0002620 (skeletal muscle satellite — N/A) — more precisely CL:0000201 (auditory hair cell) if available in the ontology used, or UBERON-anchored hair cell terms.

Biological processes: Suggested GO terms: - GO:0007605 (sensory perception of sound) - GO:0060088 (auditory receptor cell stereocilium organization) - GO:0036158 (outer dynein arm assembly — N/A, not relevant) — more appropriately GO:0032420 (stereocilium) as a cellular component and GO:0060113 (inner ear receptor cell differentiation) - Molecular function: GO:0003774 (cytoskeletal motor activity) / GO:0000146 (microfilament motor activity, actin-based motor)

Protein dysfunction category: Altered regulation/autoinhibition (a form of activating/gain-of-function dysregulation) rather than classic loss-of-function or aggregation-based misfolding — distinguishing DFNA11's mechanism from typical dominant-negative structural-protein diseases.

Subcellular localization (GO Cellular Component): Stereocilia (GO:0032420, stereocilium; specifically the upper tip-link density region of the stereocilium tip).

Not applicable/not identified in this review: No specific immune-system involvement, no described metabolic pathway alterations, and no transcriptomic/proteomic/metabolomic/lipidomic profiling datasets specific to DFNA11 human hair cells were identified (human inner-ear tissue is inherently difficult to biopsy, so most molecular profiling in this field derives from animal/organoid models rather than human patients).

7. Anatomical Structures Affected

Organ level: - Primary organ: Inner ear — specifically the cochlea (organ of Corti) for the hearing phenotype, and the vestibular labyrinth (semicircular canals, utricle, saccule) for the variable vestibular phenotype. - Body system: Auditory/vestibular sensory system (special senses). - No other organ systems are affected — this distinguishes nonsyndromic DFNA11 from syndromic USH1B (which additionally involves the retina). - Suggested UBERON terms: UBERON:0001846 (cochlea), UBERON:0002105 (vestibular organ) / UBERON:0009038 (vestibular labyrinth), UBERON:0000030 (sensory system, general).

Tissue/cell level: - Sensory epithelium of the organ of Corti — inner hair cells and outer hair cells and their stereociliary bundles. - Suggested Cell Ontology term: cochlear hair cell (best available CL term for auditory hair cells; e.g., CL:0000201, "auditory hair cell").

Subcellular level: - Stereocilia (actin-based mechanosensory protrusions on the hair-cell apical surface) — the principal subcellular site of Myo7A dysfunction. - The tip link and upper tip-link density (UTLD), a specialized subdomain at the stereocilium tip. - Suggested GO Cellular Component terms: GO:0032420 (stereocilium), GO:0032421 (stereocilium bundle), GO:0002131 (stereocilium tip [if present in ontology]).

Localization: Bilateral, symmetric involvement of both cochleae (and both vestibular labyrinths when vestibular dysfunction is present) — no lateralization pattern is described.

8. Temporal Development

Onset: Postlingual — after speech has been acquired. Reports vary: OMIM describes onset "often in the first decade of life"; other cohort/pedigree studies describe onset in the second decade (Kubota et al., PMID: 11889386) through the second-to-fifth decade depending on the specific variant/domain affected (motor-domain variants: later onset, second–fifth decade; MyTH4-domain variants: earlier onset, teens–20s) (Joo et al. 2022, PMID: 35453549).

Onset pattern: Insidious/gradual rather than acute or episodic.

Progression: Slowly progressive at high frequencies initially; low frequencies become involved later but then progress more rapidly once affected (PMID: 32097363). Audiometric configuration evolves over decades from sloping (childhood) to flat (after age ~30).

Disease course pattern: Progressive, not relapsing-remitting or episodic. No spontaneous remission is described.

Disease duration: Chronic and lifelong/progressive — hearing loss does not resolve and is expected to continue worsening with age.

Critical periods / early biomarker window: Abnormal DPOAEs can be detected before conventional audiometric threshold shifts, suggesting a preclinical detection window that could inform earlier monitoring or intervention timing (PMID: 32097363).

9. Inheritance and Population

Epidemiology: - Hearing loss overall affects approximately 1–3 per 1,000 live births, with more than half attributable to genetic causes. - Non-syndromic hearing loss is predominantly autosomal recessive (75–80% of Mendelian cases); autosomal dominant nonsyndromic hearing loss (ADNSHL, the DFNA category) accounts for roughly 20% of nonsyndromic hereditary hearing loss cases; X-linked accounts for 2–5%, mitochondrial ~1%. - Within ADNSHL specifically, 46 causative genes have been identified to date, of which MYO7A (DFNA11) is one. - DFNA11 is explicitly characterized as "the rarest consequence of the MYO7A gene variant" relative to DFNB2 and USH1B — i.e., among the three MYO7A-associated phenotypes, dominant DFNA11 is the least frequently observed clinically (Joo et al. 2022, PMID: 35453549, synthesis). - In a large post-lingual ADNSHL diagnostic cohort (Korea), MYO7A/DFNA11 variants were identified in 2.0% (6/300) of families overall and 4.1% (6/148) of multiplex families (PMID: 35453549).

Inheritance pattern: Autosomal dominant.

Penetrance: Appears high/complete within described pedigrees (all variant carriers develop hearing loss), though formal penetrance estimates were not located in this review.

Expressivity: Variable — age of onset, severity, audiometric configuration, and presence/absence of vestibular involvement vary between and within families, correlating in part with which protein domain is affected (motor vs. MyTH4 vs. IQ/coiled-coil) (PMID: 35453549).

Genetic anticipation: Not described for DFNA11 (not a repeat-expansion disorder).

Germline mosaicism: Not specifically reported for DFNA11 in this review.

Founder effects: Not specifically documented for DFNA11 variants in the sources reviewed (contrast with some MYO7A-DFNB2/USH1B populations where founder alleles are described in specific ethnic groups, e.g., South African and Chinese cohorts).

Carrier frequency: As an autosomal dominant condition with (presumably) private family-specific variants, a general population "carrier frequency" concept (as used for recessive disease) is not applicable in the same way; rather, prevalence reflects de novo occurrence plus transmission within affected pedigrees.

Consanguinity role: Not relevant to this dominant condition (relevant instead to the recessive DFNB2/USH1B end of the MYO7A spectrum).

Population demographics: DFNA11 has been reported in diverse populations including Dutch, Japanese, Korean, and Chinese pedigrees, without an established predominant ethnic enrichment specific to the dominant (as opposed to recessive) phenotype, based on the geographic spread of cited cohort studies.

Sex ratio: No sex-specific skewing is described — consistent with autosomal (non-X-linked) inheritance.

10. Diagnostics

Clinical tests: - Pure-tone audiometry: primary diagnostic tool; characteristic evolving configuration (sloping → flat) with age, as described above. - Distortion product otoacoustic emissions (DPOAE): identified as potentially useful for early/preclinical detection, showing abnormalities before conventional threshold elevation in some DFNA11 subjects (PMID: 32097363). - Vestibular function testing (e.g., caloric testing, vestibular-evoked myogenic potentials/VEMP, video head-impulse testing): used to characterize the variable vestibular component; results are family-specific (normal in some pedigrees, abnormal in others). - Ophthalmologic examination (including electroretinography): important to formally exclude retinitis pigmentosa/USH1B, given allelism at the MYO7A locus — a normal ERG supports the nonsyndromic DFNA11 diagnosis over USH1B.

Genetic testing: - Diagnosis is established by identifying a heterozygous pathogenic/likely pathogenic MYO7A variant, typically via next-generation sequencing (NGS) hearing-loss gene panels, whole-exome sequencing, or single-gene MYO7A sequence analysis, in the context of a family history consistent with autosomal dominant inheritance and a characteristic audioprofile. - GTR (Genetic Testing Registry) lists 37 clinical tests for this condition, including 31 sequence-analysis tests of the entire coding region, 23 deletion/duplication analyses, 4 targeted variant analyses, and 1 select-exon sequence analysis (NIH GTR C1832475). - Chromosomal microarray, karyotyping, and mitochondrial DNA testing are not primary diagnostic modalities for this single-gene point-variant disorder.

Differential diagnosis: Other ADNSHL genes (e.g., COCH/DFNA9, WFS1, MYO6, MYO15A, NCOA3), age-related hearing loss, noise-induced hearing loss, and — critically — USH1B (must be excluded via ophthalmologic/ERG evaluation given allelic overlap at MYO7A) and DFNB2 (excluded by dominant vs. recessive family segregation pattern).

Screening: Newborn hearing screening (universal, non-gene-specific) would detect congenital/early hearing loss but DFNA11's typically postlingual onset means it is more often identified through childhood/young-adult audiometric surveillance in known-affected families plus cascade genetic testing once a familial variant is identified. At-risk relatives can be tested to guide early monitoring (annual audiograms are recommended for progression tracking in ADNSHL generally).

11. Outcome/Prognosis

Survival/mortality: DFNA11 is not associated with increased mortality — it is an isolated sensory (auditory ± vestibular) disorder with no systemic organ involvement.

Morbidity/function: Progressive bilateral sensorineural hearing loss leading, over decades, to moderate-to-severe (and potentially profound in some MyTH4-variant cases) hearing impairment; functional impact centers on communication and, if vestibular involvement is present, balance/gait.

Disease course/complications: No systemic complications are described. The main "complication" is progression to a degree of hearing loss requiring amplification or cochlear implantation.

Recovery potential: Hearing loss is not reversible without intervention (hearing aids/cochlear implant); there is no evidence of spontaneous recovery.

Prognostic factors: Domain of the causative variant appears prognostic — motor-domain variants are associated with later onset, milder severity, and slower progression, while MyTH4-domain variants are associated with earlier onset, greater severity, and more rapid progression (PMID: 35453549). Abnormal DPOAE prior to threshold shift may serve as an early prognostic/monitoring biomarker (PMID: 32097363).

12. Treatment

DFNA11 has no gene-specific or disease-modifying pharmacotherapy; management is supportive/rehabilitative, following general ADNSHL practice:

• Hearing aids — for mild-to-moderate hearing loss (amplification). Suggested NCIT term: consider a general audiologic rehabilitation/hearing-aid-fitting procedure term if present in NCIT (no MAXO/NCIT-specific "hearing aid" clinical-action term is confirmed to exist per this repository's own documented gap — see CLAUDE.md note on lack of an NCIT equivalent for hearing-aid usage).
• Cochlear implantation — considered when hearing loss progresses to severe-to-profound levels; NCIT candidate: NCIT:C15329 (Surgical Procedure) as the closest general clinical-action term, or a more specific cochlear-implantation term if available in NCIT.
• Hybrid (electro-acoustic) devices — combining acoustic amplification for residual low-frequency hearing with electrical stimulation for high-frequency loss, relevant given DFNA11's sloping-then-flat audiometric evolution.
• Genetic counseling — NCIT:C15240 (Genetic Counseling); important for informing at-risk relatives, given autosomal dominant transmission (~50% risk to offspring of an affected individual) and variable expressivity.
• Audiologic surveillance — at least annual audiograms recommended to track progression; DPOAE monitoring may allow earlier detection of decline (PMID: 32097363).
• Noise avoidance counseling — to minimize any additional/superimposed noise-induced component to the progressive genetic loss (general ADNSHL guidance, PMC10296186).

Experimental/advanced therapeutics: No DFNA11-specific gene therapy trials were identified. However, the allelic and mechanistically related USH1B (severe MYO7A loss-of-function) has active preclinical and early clinical gene-therapy development that is instructive for the broader MYO7A therapeutic landscape: - Dual-AAV8(Y733F) vector delivery of full-length MYO7A cDNA (split into 5′/3′ halves due to the ~6.7 kb cDNA exceeding single-AAV packaging capacity) has shown improved vestibular hair-cell stereocilium morphology and vestibular function in the shaker-1 (USH1B) mouse model, though cochlear stereocilia organization and auditory function were not similarly rescued (Molecular Therapy Methods & Clinical Development, 2023). - A Phase 1/2 human trial of dual-AAV MYO7A delivery to the retina in USH1B patients ("UshTher") was designed but was placed on hold after Sanofi withdrew from the program in December 2018; the sponsor sought an out-licensing partner as of February 2019. - Third-generation lentiviral gene therapy (UshStat, EIAV-based) has also been studied preclinically in the shaker-1 mouse model. - These approaches target loss-of-function USH1B alleles and are not directly applicable to DFNA11's proposed dominant-activation mechanism, which would more likely require an allele-specific knockdown or gene-silencing (rather than gene-replacement) strategy if a targeted therapy were pursued — though no such DFNA11-specific therapeutic program was identified in this review.

Personalized medicine: Not currently applicable beyond domain-based prognostic counseling (motor vs. MyTH4 variant location informing expected course, per PMID: 35453549).

13. Prevention

• Primary prevention: Not applicable in the sense of preventing occurrence of a germline dominant variant; genetic counseling and reproductive options (e.g., preimplantation genetic testing) can be discussed with affected families who wish to reduce transmission risk, though this is standard ADNSHL counseling rather than DFNA11-specific literature.
• Secondary prevention: Early identification via audiometric (and potentially DPOAE) surveillance in known-affected families/genetically confirmed carriers, enabling earlier fitting of amplification devices and earlier educational/communication support.
• Tertiary prevention: Avoidance of additional noise exposure to prevent superimposed noise-induced threshold shifts; prompt escalation from hearing aids to cochlear implantation as thresholds decline, to minimize functional/communicative morbidity.
• Genetic/carrier screening: Cascade testing of at-risk relatives once a familial MYO7A variant is identified; prenatal/preimplantation genetic testing is an option for informed families given the well-defined dominant Mendelian pattern.
• Public health/behavioral/immunization/prophylaxis: Not applicable — DFNA11 is not preventable by vaccination, environmental intervention, or prophylactic medication.

14. Other Species / Natural Disease

Taxonomy: Mouse (Mus musculus, NCBITaxon:10090) and zebrafish (Danio rerio, NCBITaxon:7955) are the principal model species; no naturally occurring companion-animal or wildlife DFNA11-equivalent disease was identified in this review (note: some veterinary myosin-related deafness models exist for other myosin genes, but not specifically an autosomal dominant Myo7a condition analogous to DFNA11).

Orthologous gene: Mouse Myo7a (MGI ortholog of human MYO7A); zebrafish myo7aa (and paralog myo7ab).

Comparative biology: The mouse and zebrafish Myo7a-null/loss-of-function models (below) primarily recapitulate the USH1B/DFNB2 end of the phenotypic spectrum (profound congenital deafness plus vestibular dysfunction, with only mild/attenuated retinal phenotypes in mouse and zebrafish compared to human USH1B). A model specifically representing the dominant, activating DFNA11 mechanism (as opposed to loss-of-function) was not identified in the literature surveyed — this is a modeling gap, since the shaker-1 and mariner models are loss-of-function (recessive-equivalent), not dominant-activating alleles.

Transmission/zoonotic potential: Not applicable — this is a non-infectious, monogenic disorder.

15. Model Organisms

Mouse — Shaker-1 (sh1): - The first identified USH locus model (1995); a spontaneous nonsense mutation in Myo7a. - Phenotype: profound, lifelong deafness; vestibular dysfunction manifesting as head-tossing and circling behavior; disorganized cochlear hair-cell stereocilia; only minor/mild retinal defects are observed despite the human USH1B phenotype including significant retinitis pigmentosa — a notable human-model translational mismatch for the retinal component. - Represents the severe loss-of-function end of the Myo7a spectrum (USH1B-like), not the dominant-activating DFNA11 mechanism. - AAV-mediated Myo7a rescue (dual-AAV8(Y733F)) in shaker-1 mice improves vestibular hair-cell stereocilium morphology and vestibular function (reduced circling, improved VsEP thresholds) but does not similarly rescue cochlear stereocilia organization or auditory function — indicating differential rescuability of vestibular versus auditory hair cells.

Zebrafish — myo7aa mariner mutant: - Ernest et al. (2000) described a myo7aa premature-stop-codon zebrafish model of USH1B; homozygous mutants show circular swimming, defective balance, morphological/functional inner-ear hair-cell defects, and absence of the acoustic startle response. - myo7aa⁻/⁻ zebrafish also show mild photoreceptor degeneration and reduced electroretinographic responses (PMID: 24698764), again modeling USH1B rather than DFNA11 specifically. - A more recent study (Frontiers in Molecular Neuroscience, 2024) implicates zebrafish myo7aa in congenital hearing via Rho-GTPase signaling regulation, adding a signaling-pathway dimension to the mechanistic picture.

Cell-based/epithelial models: Heterologous expression systems (e.g., kidney epithelial cell lines such as MDCK-type cells) have been used to directly test DFNA11 patient-derived missense variants for their effect on Myo7A subcellular targeting/trafficking, providing the closest available model to the dominant DFNA11 mechanism itself (bioRxiv 2024.09.17.613491 / PubMed 39345484) — these assays found that DFNA11 mutations activate (rather than abolish) Myo7A targeting, distinguishing the cellular mechanism from the USH1B mistargeting phenotype.

Model limitations: No available animal model directly and specifically recapitulates the dominant, gain-of-function/activating DFNA11 mechanism in vivo (as opposed to the standard loss-of-function shaker-1/mariner alleles) — an important human-model mismatch to flag for any DFNA11 knowledge-base entry: existing Myo7a animal models are informative for general hair-cell MET biology and for the USH1B/DFNB2 severe end of the spectrum, but their applicability to DFNA11's proposed dominant-activation mechanism and its comparatively mild, slowly progressive phenotype is not established.

Resources: MGI (Mouse Genome Informatics) for shaker-1 allele records; ZFIN for zebrafish myo7aa mariner allele records; IMSR/EMMA for repository access to Myo7a mouse strains.

Summary of Key Primary Citations

Notes on Information Gaps

• Direct OMIM #601317 full-text clinical synopsis and the primary GeneReviews MYO7A chapter could not be fetched directly (403/cookie-wall errors); content above synthesizes OMIM/GTR summaries obtained via search snippets and secondary sources, and should be cross-checked against the primary OMIM clinical synopsis and GeneReviews "MYO7A-Related Hearing Loss and Retinitis Pigmentosa" chapter when curating a formal knowledge-base entry.
• No gnomAD constraint metrics (pLI/LOEUF/missense Z) specific to MYO7A were retrieved in this pass; these should be pulled directly from gnomAD for the knowledge-base entry.
• No dedicated DFNA11 prevalence/incidence rate (cases per 100,000) was located; only the general ADNSHL proportion (~20% of nonsyndromic hereditary hearing loss) and MYO7A's cohort-level diagnostic yield (2.0–4.1% of postlingual ADNSHL families in one Korean cohort) are available as proxies.
• The mechanistic bioRxiv paper (39345484) appears to have been a preprint at the time of search; verify final peer-reviewed publication status/PMID before final curation.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:32097363 (abstract only): "remained normal across all tested subjects"
• closest text in source: "Vestibular function was within the normal range in all the subjects tested"